Skip to content
DraconiticResearch
Search Sources API
197,787 studies31 sourcesUpdated 43 min ago
PreprintCC BY-NCmedRxiv

'We need this now': Acceptability and usability of a pediatric antiretroviral microarray patch prototype in South Africa and Uganda

  1. 1PATH Seattle, Washington, USA

Abstract

Children living with HIV face significant challenges with adherence to daily oral antiretroviral (ARV) treatment due to poor palatability, complicated dosing, and caregiver burden. Long-acting delivery systems designed specifically for children may help overcome these barriers. Microarray patches, also known as microneedle patches, are a needle-free drug delivery technology that could simplify treatment administration and improve adherence. This study explored the acceptability and usability of a pediatric ARV microarray patch prototype among stakeholders in South Africa and Uganda, two countries with a high burden of pediatric HIV.

A formative study was conducted in 2024 with 48 participants, including caregivers, community health workers, health care providers, and decision-makers. Data were collected through qualitative methods: interviews, simulated use sessions, and observations. Participants demonstrated high usability of the prototype, with 97% completing all application steps and nearly all reporting the prototype as easy to use and expressing confidence in successful administration. Most participants found the prototypes size, wear time, and temporary skin changes acceptable, and all preferred a weekly patch over daily oral treatment. Applying multiple patches at once to achieve a therapeutic dose was considered feasible. Decision-makers foresaw strong programmatic fit of a pediatric ARV microarray patch if caregivers apply the patch at home following initial facility-based guidance.

Overall, the pediatric ARV microarray patch prototype was perceived as highly acceptable and usable across diverse end users, findings that generally align with studies of microarray patches for other use cases (e.g., contraception, HIV pre-exposure prophylaxis, vaccine delivery). The simplicity, comfort, and convenience of a pediatric ARV microarray patch could substantially improve treatment adherence and quality of life for children living with HIV. Further development and clinical evaluation are warranted to advance this promising technology toward real-world use.

Related

  1. Usability and Acceptability of a Mobile Food Record in Free-Living Athletes: A Single-Group Observational Study
    Fabricio Forchino, Dale W. Chapman, Carly J. Brade +3
    NutrientsPeer-reviewedCC BYFull textNutritionEurope PMC
  2. Feasibility, acceptability and usability of InControl web-platform intervention for older adults with chronic musculoskeletal pain: A mixed-methods pilot study protocol
    David Oliveira, Nelson P. Rocha, Anabela G. Silva
    PLOS OnePeer-reviewedCC BY 4.0Full textClinical trials & evidence synthesisPLOS
  3. Acceptability and usability of home-based HIV and blood glucose self-testing and home-based blood pressure measurement in Kenya, South Africa, and Zambia
    Carolyn R. Oliver, Meagan J. Bemer, Amber Lauff +10
    PLOS Global Public HealthPeer-reviewedCC BY 4.0Full textMicrobiologyPhysiologyPLOS
  4. Prospective Acceptability and Usability of a WhatsApp Chatbot for Epidemic Response in Malawi: Convergent Mixed Methods Study
    Selemani Ngwira, Tsung-Shu Joseph Wu, Isaach Ndemera +9
    JMIR Formative ResearchPeer-reviewedCC BY 4.0Full textGeneral medicineDOAJPMC
  5. Usability, acceptability and feasibility of continuous glucose monitoring among children and adolescents with type 1 diabetes in Kenya
    P. Amolo, L. Mungai, A. K. Karume +6
    medRxivPreprintCC BY-NCFull textEndocrinology & metabolismmedRxiv
BibTeX
@misc{quintanarsolares2026need,
  title = {{'We need this now': Acceptability and usability of a pediatric antiretroviral microarray patch prototype in South Africa and Uganda}},
  author = {M. Quintanar-Solares and J. K. Tumusiime and P. Mbotho and N. Ngcobo and P. Kwarteng and T. Sibaya and J. J. Mistilis and M. Archary and R. K. M. Choy},
  howpublished = {medRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.17.26363333},
  url = {https://www.medrxiv.org/content/10.64898/2026.09.17.26363333v1},
  note = {CC BY-NC},
}
RIS
TY  - UNPB
TI  - 'We need this now': Acceptability and usability of a pediatric antiretroviral microarray patch prototype in South Africa and Uganda
AU  - M. Quintanar-Solares
AU  - J. K. Tumusiime
AU  - P. Mbotho
AU  - N. Ngcobo
AU  - P. Kwarteng
AU  - T. Sibaya
AU  - J. J. Mistilis
AU  - M. Archary
AU  - R. K. M. Choy
PY  - 2026
DA  - 2026/09/17
PB  - medRxiv
DO  - 10.64898/2026.09.17.26363333
UR  - https://www.medrxiv.org/content/10.64898/2026.09.17.26363333v1
AB  - Children living with HIV face significant challenges with adherence to daily oral antiretroviral (ARV) treatment due to poor palatability, complicated dosing, and caregiver burden. Long-acting delivery systems designed specifically for children may help overcome these barriers. Microarray patches, also known as microneedle patches, are a needle-free drug delivery technology that could simplify treatment administration and improve adherence. This study explored the acceptability and usability of a pediatric ARV microarray patch prototype among stakeholders in South Africa and Uganda, two countries with a high burden of pediatric HIV.  A formative study was conducted in 2024 with 48 participants, including caregivers, community health workers, health care providers, and decision-makers. Data were collected through qualitative methods: interviews, simulated use sessions, and observations. Participants demonstrated high usability of the prototype, with 97% completing all application steps and nearly all reporting the prototype as easy to use and expressing confidence in successful administration. Most participants found the prototypes size, wear time, and temporary skin changes acceptable, and all preferred a weekly patch over daily oral treatment. Applying multiple patches at once to achieve a therapeutic dose was considered feasible. Decision-makers foresaw strong programmatic fit of a pediatric ARV microarray patch if caregivers apply the patch at home following initial facility-based guidance.  Overall, the pediatric ARV microarray patch prototype was perceived as highly acceptable and usable across diverse end users, findings that generally align with studies of microarray patches for other use cases (e.g., contraception, HIV pre-exposure prophylaxis, vaccine delivery). The simplicity, comfort, and convenience of a pediatric ARV microarray patch could substantially improve treatment adherence and quality of life for children living with HIV. Further development and clinical evaluation are warranted to advance this promising technology toward real-world use.
ER  -